Medical Devices DECODED
Previous edition: 03 Apr 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Abbott's bedside concussion blood test scores FDA clearance
Abbott’s rapid whole blood test can be used for bedside assessment of mild traumatic brain injury (mTBI) or concussion.
The US Food and Drug Administration (FDA) has cleared Abbott’s i-STAT TBI cartridge for assessing patients with suspected concussion or mild traumatic brain injury (mTBI).
The current standard for assessing TBI is a subjective doctor assessment via a Glasgow Coma Scale and a computed tomography (CT) scan, which can be time-consuming and require specialised personnel.
The portable i-STAT TBI cartridge uses whole blood to screen for two serum biomarkers, ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP). Elevation of these biomarkers indicates a severe injury, thereby, informing the need for conducting a CT scan. The test can used to objectively assess patients with suspected concussion.
The test can be performed in emergency settings and gives out results in approximately 15 minutes. The test is cleared for use in patients aged 18 years and older. Furthermore, it can used to evaluate patients for concussions up to 24 hours after injury.
Abbott plans to seek expanded clearance for the test that allows i-STAT TBI cartridge use in non-healthcare settings such as sporting events, and with a broader population, including teens and paediatrics.
Abbott developed the i-STAT TBI blood test in partnership with the US Department of Defense (DoD). In 2014, Abbott received a $19.5m grant from the DoD to assess and verify mTBI biomarkers that can be used for rapid battlefield assessment of concussions.
The development of rapid tests has increased in recent years, which was fuelled by the use of rapid testing during the Covid-19 pandemic. The market for point of care (POC) diagnostic tests was worth approximately $297.6bn last year, according to GlobalData analysis.
Another test for assessing concussion is Marker Diagnostics’ saliva-based test, MTx.100. The test measures the expression of small non-coding RNA (sncRNA) biomarkers found in saliva to diagnose concussion. It is being evaluated as a concussion diagnostic for sportspersons in a study with women rugby players.
Latest news
Concept wins another IDE from FDA for MagicTouch range
Concept’s sirolimus-coated balloons now hold five IDEs in total from the FDA.
Protembis enrols first patient for ProtEmbo System trial
The trial will assess the ProtEmbo System, a cerebral protection device used during TAVR procedures.
FDA approves Abbott's TriClip system for tricuspid valve repair
TriClip is a less invasive alternative to open-heart surgery for patients for whom surgical intervention is not suitable.
Tethis enrols first two subjects in trial of See.d instrument
The study will provide first ‘real world’ data on the See.d instrument's performance and ease of use in hospital environment.
13th Annual Clinical Trial Supply New England 2024
The upcoming Clinical Trial Supply Europe 2024 conference will gather pharma and biotech delegates to discuss the trends and challenges in the clinical trial supply industry.
Kelyniam and Finceramica announce FDA clearance for NEOS system
The NEOS Surgery Cranial LOOP offers quick implant fixation process, requiring only three devices.
Fractyl Health receives IDE approval for Revita trial
The trial will assess Revita’s efficacy in maintaining weight loss following the discontinuation of its GLP-1 receptor agonist (GLP-1RA) drug therapy.
In our previous edition
Medical Devices Decoded
Fractyl Health receives IDE approval for Revita trial
02 Apr 2024
Medical Devices Decoded
J&J reportedly eyeing Shockwave Medical for takeover
28 Mar 2024
Medical Devices Decoded
Cleerly touts new data for AI cardiovascular software
27 Mar 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Medical Devices
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer